Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Executive Summary
Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.
You may also be interested in...
Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH
Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.